Data gathered: April 4
Alternative Data for Bluebird bio
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 86 | Sign up | Sign up | Sign up |
| Webpage traffic | 20,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | 11 | Sign up | Sign up | Sign up |
| Patents | 71 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Instagram Followers | 3,198 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 228 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,965 | Sign up | Sign up | Sign up |
| Twitter Followers | 10,382 | Sign up | Sign up | Sign up |
| Twitter Mentions | 152 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,790 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $20,000 | Sign up | Sign up | Sign up |
| Business Outlook | 33 | Sign up | Sign up | Sign up |
| Linkedin Employees | 514 | Sign up | Sign up | Sign up |
About Bluebird bio
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases.
| Price | $4.83 |
| Target Price | Sign up |
| Volume | 12,050 |
| Market Cap | $49M |
| Year Range | $3.73 - $24.4 |
| Dividend Yield | 0% |
| Analyst Rating | 25% buy |
| Industry | Biotechnology |
In the news
 |
Charles Schwab Investment Management Inc. Sells 525,408 Shares of bluebird bio, Inc. (NASDAQ:BLUE)April 2 - ETF Daily News |
|
Barclays Cuts bluebird bio (NASDAQ:BLUE) Price Target to $8.00April 1 - ETF Daily News |
|
Brokerages Set bluebird bio, Inc. (NASDAQ:BLUE) PT at $51.00March 30 - ETF Daily News |
 |
bluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.comMarch 29 - ETF Daily News |
 |
Bluebird bio receives non-binding bid for up to $110.5 millionMarch 28 - Yahoo |
|
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue EstimatesMarch 27 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 11M | 12M | -1.2M | -61M | -52M | -0.310 |
| Q2 '24 | 16M | 29M | -13M | -81M | -72M | -8.400 |
| Q1 '24 | 19M | 26M | -7.3M | -70M | -49M | -7.200 |
| Q4 '23 | 7.8M | 9.6M | -1.8M | -89M | -57M | -15.600 |
| Q3 '23 | 12M | 9.1M | 3.3M | -87M | -84M | -0.660 |
Insider Transactions View All
| Obenshain Andrew filed to sell 18,327 shares at $3.9. March 5 '25 |
| Klima Thomas J filed to sell 7,878 shares at $3.9. March 5 '25 |
| Colvin Richard A filed to sell 7,610 shares at $3.9. March 5 '25 |
| Obenshain Andrew filed to sell 18,485 shares at $7.4. February 5 '25 |
| Colvin Richard A filed to sell 8,194 shares at $7.4. February 5 '25 |
Similar companies
Read more about Bluebird bio (BLUE) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Bluebird bio?
The Market Cap of Bluebird bio is $49M.
What is the current stock price of Bluebird bio?
Currently, the price of one share of Bluebird bio stock is $4.83.
How can I analyze the BLUE stock price chart for investment decisions?
The BLUE stock price chart above provides a comprehensive visual representation of Bluebird bio's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Bluebird bio shares. Our platform offers an up-to-date BLUE stock price chart, along with technical data analysis and alternative data insights.
Does BLUE offer dividends to its shareholders?
As of our latest update, Bluebird bio (BLUE) does not offer dividends to its shareholders. Investors interested in Bluebird bio should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Bluebird bio?
Some of the similar stocks of Bluebird bio are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.